Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-01-29 Sale |
2025-01-30 6:44 pm |
DEXCOM INC | DXCM | Dolan Matthew Vincent EVP, Strategy & Corporate Dev |
1,183 | $86.91 | $102,820 | 42,044 (Direct) |
View |
| 2024-05-15 Sale |
2024-05-16 4:04 pm |
DEXCOM INC | DXCM | Dolan Matthew Vincent EVP Strategy and Corporate Dev |
2,423 | $126.58 | $306,703 | 40,075 (Direct) |
View |
| 2024-04-15 Sale |
2024-04-16 4:16 pm |
DEXCOM INC | DXCM | Dolan Matthew Vincent EVP Strategy and Corporate Dev |
1,990 | $137.81 | $274,242 | 42,377 (Direct) |
View |
| 2024-03-15 Sale |
2024-03-19 4:55 pm |
DEXCOM INC | DXCM | Dolan Matthew Vincent EVP Strategy & Corp Dev |
4,203 | $130.21 | $547,259 | 44,367 (Direct) |
View |
| 2024-03-12 Sale |
2024-03-14 5:39 pm |
DEXCOM INC | DXCM | Dolan Matthew Vincent EVP Strategy and Corporate |
6,710 | $134.41 | $901,896 | 48,570 (Direct) |
View |
| 2023-09-01 Sale |
2023-09-01 6:40 pm |
DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Strategy-Develop |
56 | $102.32 | $5,730 | 33,569 (Direct) |
View |
| 2023-03-16 Sale |
2023-03-17 4:14 pm |
DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Strategy-Develop |
2,303 | $115 | $264,845 | 33,569 (Direct) |
View |
| 2023-03-10 Sale |
2023-03-14 4:46 pm |
DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Strategy-Develop |
12,433 | $108.83 | $1,353,075 | 35,872 (Direct) |
View |
| 2023-03-06 Sale |
2023-03-06 8:04 pm |
DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Strategy-Develop |
226 | $114.4 | $25,854 | 26,536 (Direct) |
View |
| 2022-09-01 Sale |
2022-09-06 09:33 am |
DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Strategy-Develop |
5 | $81.63 | $408 | 26,536 (Direct) |
View |
| 2022-03-15 Sale |
2022-03-17 4:30 pm |
DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Development |
2,186 | $424.68 | $928,359 | 6,634 (Direct) |
View |
| 2022-03-09 Sale |
2022-03-10 7:24 pm |
DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Development |
1,615 | $406.06 | $655,782 | 8,820 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-01-28 Option Award |
2025-01-30 6:44 pm |
N/A N/A |
DEXCOM INC | DXCM | Dolan Matthew Vincent EVP, Strategy & Corporate Dev |
3,048 | $0 | 42,044 (Direct) |
View |
| 2024-03-08 Option Award |
2024-03-11 6:30 pm |
N/A N/A |
DEXCOM INC | DXCM | Dolan Matthew Vincent EVP Strategy and Corporate |
21,711 | $0 | 55,280 (Direct) |
View |
| 2023-03-08 Option Award |
2023-03-10 4:00 pm |
N/A N/A |
DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Strategy-Develop |
21,769 | $0.001 | 48,305 (Direct) |
View |
| 2022-03-08 Option Award |
2022-03-10 7:24 pm |
N/A N/A |
DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Development |
2,889 | $0.001 | 8,820 (Direct) |
View |
Ownership |
2022-03-10 5:39 pm |
N/A N/A |
DEXCOM INC | DXCM | Dolan Matthew Vincent * |
0 | $0 | 7,546 (Direct) |
View |